Etanercept is safely used for treating psoriatic arthritis in a patient complicated with type 1 hereditary angioedema

Noriko Umegaki, Masahiro Kira, Takahiko Horiuchi, Saori Itoi, Mamori Tani, Akinori Yokomi, Atsushi Tanemura, Hisaaki Miyahara, Michiyo Hatanaka, Hajime Kitamura, Etsuko Kitano, Ichiro Katayama

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hereditary angioedema (HAE) is a life-threatening disorder caused by deficiency or dysfunction of the C1 inhibitor protein. Patients with HAE are restricted in various medical treatments, which can induce an HAE attack. We herein report the first case of psoriatic arthritis (PSA) with type 1 HAE successfully treated with 25 mg of etanercept without HAE attack. Etanercept may represent a useful choice for treating patients with HAE accompanied by intractable PSA and rheumatoid arthritis (RA).

Original languageEnglish
Pages (from-to)928-930
Number of pages3
JournalModern rheumatology
Volume22
Issue number6
DOIs
Publication statusPublished - 2012 Nov 1

    Fingerprint

Keywords

  • Biological agent
  • Etanercept
  • Hereditary angioedema
  • Psoriatic arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Umegaki, N., Kira, M., Horiuchi, T., Itoi, S., Tani, M., Yokomi, A., Tanemura, A., Miyahara, H., Hatanaka, M., Kitamura, H., Kitano, E., & Katayama, I. (2012). Etanercept is safely used for treating psoriatic arthritis in a patient complicated with type 1 hereditary angioedema. Modern rheumatology, 22(6), 928-930. https://doi.org/10.1007/s10165-012-0604-2